Strategy
Verona Pharma is rising high with the newly-launched chronic obstructive pulmonary disease drug Ohtuvayre but its development would have been severely compromised if it had not been for government benefits, non-executive chair David Ebsworth tells Scrip.
Coherus agreed to sell its biosimilar of Amgen’s Neulasta to Intas in a deal that will clear significant near-term debt and provide funds for a label-expansion strategy for its PD-1 agent Loqtorzi.
The company’s CD40 agonist mitazalimab has impressed in Phase II trials as a potential treatment for pancreatic cancer but with no partner in place yet and a lack of funds, Alligator has to cut 70% of its staff to keep going.
The Carlyle-backed venture capital group is said to be working on a new fund to help finance up to eight late-stage clinical studies through potential partnerships with big pharma for a share of royalties. The move would be in keeping with its recent investment activities.
While most drug development in the multiple sclerosis space has focused just on relapse prevention, Immunic’s dual-acting therapy vidofludimus calcium also offers a novel approach for neurodegeneration, its CEO Daniel Vitt tells Scrip.
Roche's blockbuster ophthalmic drug set for China reimbursement list inclusion in three indications and shows positive interim results in PCV.
Celltrion Group chairman outlines new plans for the Korean biosimilars giant to move into the CDMO sector and updates on new drug development activities.
The Norwegian biotech is losing a big pharma partner and up to half of its staff, but remains confident about the prospects for its personalized cancer vaccine programs.
Both companies are seeking to license their products as they try to stretch their dwindling cash.
Deal Snapshot: The essential tremor space has not seen innovation in treatment for decades. Acadia believes Saniona's GABAA-α3 positive allosteric modulator could be the answer.
The Swiss major’s chief medical officer tells Scrip about how “an R&D/commercial continuum” is helping to speed up innovation across the group.
CEO Vas Narasimhan has highlighted the strong momentum from six new products plus the old favorites Entresto and Cosentyx, saying that there are over 30 high-value medicines in the pipeline that will drive continued mid-single digit sales growth beyond 2029.
The company is trading below cash after admitting that an adverse event in a Rett syndrome trial left a patient critically ill.
Sun and other major Indian firms outline how things are shaping up for products and manufacturing in China - while it’s a mixed bag, the wider outlook is upbeat. M&A and GLP-1 plays were among other key areas discussed during Q2 earnings.
After completing due diligence, private equity firm Brookfield is reportedly close to launching an offer of €10.50 euros per share to acquire the Spanish major. Given that at least one investor believes Grifols is worth at least €20 a share, sparks could fly.
The US firm wants to hook up with the German group to create a global innovative services company but its €11.00 per share cash offer looks unlikely to sway Evotec shareholders.
Yuhan eyes successors to lazertinib after US approval, leadership dispute at Hanmi drags on and SK Bioscience completes CDMO acquisition.
The German major’s CEO Bill Anderson will not be tempted to go out and make a big bid on a late-stage asset to fill the revenue gap caused by Xarelto’s patent expiries, telling Scrip that " in the pharma business, that's pretty much worse than going to the casino.”
At a recent conference, executives from Boehringer and Amgen laid out their expectations for the future of obesity and how they intend to navigate the changes.
The Spanish company's Lilly-partnered atopic dermatitis drug is enjoying a decent launch in Germany and in other European countries, "we are getting the price that we wanted," claims CEO Carlos Gallardo.